| pubmed-article:21233252 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:21233252 | lifeskim:mentions | umls-concept:C0052441 | lld:lifeskim |
| pubmed-article:21233252 | lifeskim:mentions | umls-concept:C0018787 | lld:lifeskim |
| pubmed-article:21233252 | lifeskim:mentions | umls-concept:C0013089 | lld:lifeskim |
| pubmed-article:21233252 | lifeskim:mentions | umls-concept:C1280500 | lld:lifeskim |
| pubmed-article:21233252 | lifeskim:mentions | umls-concept:C0086597 | lld:lifeskim |
| pubmed-article:21233252 | lifeskim:mentions | umls-concept:C1879547 | lld:lifeskim |
| pubmed-article:21233252 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:21233252 | pubmed:dateCreated | 2011-4-19 | lld:pubmed |
| pubmed-article:21233252 | pubmed:abstractText | Doxorubicin (DOX) is a highly effective chemotherapeutic agent; however, cumulative dose-dependent cardiotoxicity is a significant side effect of this therapy. Because DOX is a polyaromatic hydrocarbon, we hypothesized that it will be metabolized by the activation of the aryl hydrocarbon receptor (AhR), a ligand-activated transcription factor that is involved in the metabolism of numerous xenobiotic agents. These studies were performed to determine whether DOX activates AhR and whether this activation modulates the toxicity of DOX in cardiomyocytes. | lld:pubmed |
| pubmed-article:21233252 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21233252 | pubmed:language | eng | lld:pubmed |
| pubmed-article:21233252 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21233252 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:21233252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21233252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21233252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21233252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21233252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21233252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21233252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21233252 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:21233252 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:21233252 | pubmed:month | May | lld:pubmed |
| pubmed-article:21233252 | pubmed:issn | 1755-3245 | lld:pubmed |
| pubmed-article:21233252 | pubmed:author | pubmed-author:RussellKerry... | lld:pubmed |
| pubmed-article:21233252 | pubmed:author | pubmed-author:VolkovaMariaM | lld:pubmed |
| pubmed-article:21233252 | pubmed:author | pubmed-author:RussellRaymon... | lld:pubmed |
| pubmed-article:21233252 | pubmed:author | pubmed-author:PalmeriMonica... | lld:pubmed |
| pubmed-article:21233252 | pubmed:issnType | Electronic | lld:pubmed |
| pubmed-article:21233252 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:21233252 | pubmed:volume | 90 | lld:pubmed |
| pubmed-article:21233252 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:21233252 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:21233252 | pubmed:pagination | 305-14 | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:meshHeading | pubmed-meshheading:21233252... | lld:pubmed |
| pubmed-article:21233252 | pubmed:year | 2011 | lld:pubmed |
| pubmed-article:21233252 | pubmed:articleTitle | Activation of the aryl hydrocarbon receptor by doxorubicin mediates cytoprotective effects in the heart. | lld:pubmed |
| pubmed-article:21233252 | pubmed:affiliation | Section of Cardiovascular Medicine, Yale University School of Medicine, 333 Cedar Street, FMP 3, New Haven, CT 06520, USA. | lld:pubmed |
| pubmed-article:21233252 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:21233252 | pubmed:publicationType | Research Support, N.I.H., Extramural | lld:pubmed |
